Biologics for inherited disorders of keratinisation: A systematic review

医学 皮肤病科 乌斯特基努马 梅德林 塞库金单抗 不利影响 儿科 英夫利昔单抗 内科学 银屑病 疾病 政治学 法学 银屑病性关节炎
作者
Michelle K. Y. Chen,Alice L. Flanagan,Deshan F. Sebaratnam,Yaron Gu
出处
期刊:Australasian Journal of Dermatology [Wiley]
卷期号:65 (2): 185-214 被引量:10
标识
DOI:10.1111/ajd.14197
摘要

Abstract Background/Objectives Recent literature highlights the potential of biologics in the management of inherited disorders of keratinisation. In this study, we conducted a systematic review of existing literature on treatment outcomes of inherited keratinisation disorders treated with biologics. Methods Eligible records were retrieved through searches of the electronic databases MEDLINE, Embase, PubMed and Scopus. Databases were searched from inception to July 2023 for eligible records. A snowballing method was employed to search the references of the retrieved records for the identification of potentially relevant articles. Results One hundred and four eligible studies consisting of a total of 166 patients with an inherited disorder of keratinisation were included. Patients had a median age of 19 years (range: 0.5 to 70 years). The most common disorders were Netherton syndrome ( n = 63; 38%), autosomal recessive congenital ichthyoses ( n = 27; 16%), CARD14‐associated papulosquamous eruptions ( n = 17; 10%) and familial pityriasis rubra pilaris (PRP) ( n = 15; 9%).Of the 207 times biologics were employed, the three most frequently employed biologics were secukinumab ( n = 47; 23%), dupilumab ( n = 44; 21%) and ustekinumab ( n = 37; 18%). Complete remission was observed in 10 (5%) instances, partial remission in 129 (62%), no or limited response to biologic therapy in 68 (32%) cases, and results are still pending in one case. A total of 33 adverse events were reported. Conclusions Whilst biologics may be considered in cases of inherited keratinisation disorders recalcitrant to standard therapy, definitive conclusions are prohibited by the low‐level of evidence and substantial heterogeneity in methodology across the included studies. Establishment of consensus definitions, and randomised clinical trials may help ascertain the efficacy and safety of biologic therapy in this context and establish the best agent and dosing protocol for each disorder.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
零知识完成签到 ,获得积分10
1秒前
1秒前
欢呼冥茗发布了新的文献求助10
2秒前
黑猫警长发布了新的文献求助10
2秒前
共享精神应助是关心采纳,获得10
2秒前
2秒前
叼毛发布了新的文献求助10
3秒前
3秒前
甜蜜阑悦发布了新的文献求助10
3秒前
4秒前
4秒前
LI完成签到,获得积分10
4秒前
Nokia应助senli2018采纳,获得10
4秒前
Fly发布了新的文献求助10
4秒前
4秒前
a1245105069发布了新的文献求助10
4秒前
4秒前
5秒前
欢喜代桃发布了新的文献求助10
5秒前
5秒前
晓静发布了新的文献求助10
6秒前
likenan完成签到,获得积分20
6秒前
这就是你发布了新的文献求助10
6秒前
7秒前
7秒前
7秒前
7秒前
FashionBoy应助xy采纳,获得10
8秒前
丘比特应助awa606采纳,获得10
8秒前
9秒前
9秒前
9秒前
共享精神应助晚秋采纳,获得10
9秒前
9秒前
斯文败类应助皆非采纳,获得10
10秒前
科研通AI6.2应助Elaine采纳,获得10
10秒前
FashionBoy应助没有稗子采纳,获得20
11秒前
小牛同志发布了新的文献求助10
11秒前
Nole应助jie采纳,获得10
11秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
48V Low-voltage Power Distribution Network (PDN) Architecture Industry Report, 2024 800
ズームレンズの光学設計に関する研究 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7294359
求助须知:如何正确求助?哪些是违规求助? 8912778
关于积分的说明 18870568
捐赠科研通 6960779
什么是DOI,文献DOI怎么找? 3210045
关于科研通互助平台的介绍 2379398
邀请新用户注册赠送积分活动 2186287